Amosulalol: Difference between revisions

Amosulalol
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name (RS)-5-[1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl]-2-methylbenzenesulfonamide;
CAS Number	85320-68-9 ;
PubChem CID	2169;
ChemSpider	2084 ;
UNII	C69JI1BAU8;
KEGG	D07451 ;
ChEMBL	ChEMBL152231 ;
CompTox Dashboard (EPA)	DTXSID90868893 ;
Chemical and physical data
Formula	C18H24N2O5S
Molar mass	380.46 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=C(C=C1)C(CNCCOC2=CC=CC=C2OC)O)S(=O)(=O)N;
	InChI InChI=1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23) ; Key:LVEXHFZHOIWIIP-UHFFFAOYSA-N ;
	(verify)

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 07:44, 2 March 2021

Amosulalol (INN) is an anti-hypertensive drug. It has much higher affinity for alpha-1 adrenergic receptors than for beta adrenergic receptors.^[1]

It is not approved for use in the United States.

References

^ Sponer G, Bartsch W, Hooper RG (1990). "Drugs acting on multiple receptors: β-blockers with additional properties.". Pharmacology of antihypertensive therapeutics. Handbook of Experimental Pharmacology. Vol. 93. Berlin, Heidelberg: Springer. pp. 131–226 (183). doi:10.1007/978-3-642-74209-5_5. ISBN 978-3-642-74209-5.

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.

[1] Sponer G, Bartsch W, Hooper RG (1990). "Drugs acting on multiple receptors: β-blockers with additional properties.". Pharmacology of antihypertensive therapeutics. Handbook of Experimental Pharmacology. Vol. 93. Berlin, Heidelberg: Springer. pp. 131–226 (183). doi:10.1007/978-3-642-74209-5_5. ISBN 978-3-642-74209-5.

[1]

@@ Line 52: / Line 52: @@
 }}
-'''Amosulalol''' ([[International Nonproprietary Name|INN]]) is an anti-hypertensive drug. It has much higher affinity for alpha-1 adrenergic receptors than for beta adrenergic receptors.<ref>{{cite book |title=Pharmacology of Antihypertensive Therapeutics |url=https://archive.org/details/pharmacologyofan0093unse |url-access=registration |date=1990 |publisher=Springer |pages=[https://archive.org/details/pharmacologyofan0093unse/page/180 180]-183}}</ref>
+'''Amosulalol''' ([[International Nonproprietary Name|INN]]) is an anti-hypertensive drug. It has much higher affinity for alpha-1 adrenergic receptors than for beta adrenergic receptors.<ref>{{cite book | vauthors = Sponer G, Bartsch W, Hooper RG | chapter = Drugs acting on multiple receptors: β-blockers with additional properties. | title = Pharmacology of antihypertensive therapeutics | date = 1990 | pages = 131–226 (183) | publisher = Springer | location = Berlin, Heidelberg | series = Handbook of Experimental Pharmacology | volume = 93 | doi = 10.1007/978-3-642-74209-5_5 | isbn = 978-3-642-74209-5 | chapter-url = https://archive.org/details/pharmacologyofan0093unse }}</ref>
 It is not approved for use in the United States.

v t e Beta blockers (C07)
β, non-selective	Alprenolol Bopindolol Bupranolol Carteolol Cloranolol Mepindolol Nadolol Oxprenolol Penbutolol Pindolol/Iodopindolol Propranolol^# Sotalol Tertatolol Timolol^#
β₁-selective	Acebutolol Atenolol Betaxolol Bevantolol Bisoprolol^# Celiprolol Epanolol Esmolol Landiolol Metoprolol Nebivolol Practolol Talinolol
β₂-selective	Butaxamine
α₁- + β-selective	Arotinolol Carvedilol Labetalol
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III